

- Riociguat is the first member of a novel class of therapeutics called soluble guanylate cyclase (sGC) stimulators, and is approved for the treatment of WHO Group I pulmonary arterial hypertension (PAH) and WHO Group 4 chronic thromboembolic pulmonary hypertension (CTEPH).
- The cases presented in this report represent three of the many patients with PAH whom we have treated with riociguat at our center—a large, urban, pulmonary hypertension treatment facility.
- Riociguat therapy improved exercise capacity, WHO functional class, and time to clinical worsening in patients with PAH of various etiologies.
- Improvements were seen when riociguat was used as both first-line treatment and as sequential add-on therapy.

This summary slide represents the opinions of the authors. Article processing charges for this article were funded by Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. Medical writing and editing assistance were provided by Adelphi Communications. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).